AbCellera Biologics Inc. reported significant financial developments in its 2025 fiscal year, with total revenue reaching $75.1 million, a substantial increase of 161% from $28.8 million in 2024. This growth was primarily driven by a $36 million settlement from patent litigation with Bruker Cellular Analysis, alongside a notable rise in licensing and royalty revenue, which surged to $46.9 million from just $1.0 million the previous year. However, the company also faced increased operating expenses, totaling $292.2 million, down from $343.6 million in 2024, largely due to a significant reduction in depreciation and impairment charges.
The company’s research and development expenses rose by 12% to $186.8 million, reflecting ongoing investments in its internal pipeline and clinical trials. AbCellera initiated clinical trials for its first two internal drug candidates, ABCL635 and ABCL575, in 2025, with expectations for topline data readouts in Q3 and Q4 of 2026, respectively. The company also advanced two additional candidates, ABCL688 and ABCL386, into IND-enabling studies, anticipating further clinical trials in 2027.
As of December 31, 2025, AbCellera reported approximately $533.8 million in cash, cash equivalents, and marketable securities, a decrease from $625.6 million in 2024. The decline was attributed to cash flow used in operations and investments in its corporate headquarters and clinical manufacturing facility. The company believes its available liquidity will be sufficient to meet its operational needs for at least the next three years, despite ongoing losses expected in the near term.
AbCellera's operational metrics indicate a focus on internal development, with 104 partner-initiated programs started and 19 molecules advancing into clinical stages. The company has shifted its strategy from a partnership-focused model to developing its own pipeline of drug candidates, which it believes will enhance its long-term value. The company’s workforce has grown to 562 employees, with a significant portion dedicated to research and development.
Looking ahead, AbCellera aims to leverage its competitive advantages in antibody discovery and development to create innovative medicines. The company acknowledges the inherent risks in drug development, including regulatory challenges and market competition, but remains optimistic about its strategic direction and the potential for future revenue generation from its internal programs and partnerships.
About AbCellera Biologics Inc.
AbCellera Biologics Inc. specializes in discovering and developing antibody-based medicines for diseases with high unmet needs. The company integrates advanced technology, data science, and automation to accelerate antibody drug discovery from target identification to clinical candidate delivery. Serving biotechnology and pharmaceutical partners primarily in the U.S. and Europe, AbCellera’s business model combines proprietary internal programs with strategic collaborations, generating value through milestone payments, royalties, and equity stakes.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.